Skip to main content
Loading...
Menu social network
LinkedIn
Facebook
X
Youtube
Menu top
Assistance
User account menu
Log in
Main navigation
Home
Programme
Download the app
App
Download the app
App
Menu
Login
Close
Main navigation mobile
Home
Programme
Menu top
Assistance
Menu social network
LinkedIn
Facebook
X
Youtube
32 results
D3.01 - Association between allergen-related antibodies and clinical phenotypes of IgG4-related disease (IgG4-RD)
D3.02 - A Well-Established Drug and A Rare Reaction: Successful Desensitization to Adalimumab
D3.04 - Sensitization Pattern and Characteristics of IgE Repertoire in Allergic Children with Excessively High Serum IgE Levels
D3.13 - Molecular characterization of food allergens in a case of suspected honey and mustard allergy
D3.14 - IgE sensitisation to parvalbumin, Ani s 1, tropomyosin and arginine kinase delineates distinct molecular endotypes of seafood allergy
D3.03 - Titanium allergy – from anamnesis to diagnosis
D3.06 - Comparative Evaluation of Raw, Blanched, Individual and Composite Allergen Preparation for Basophil Activation Testing
D3.07 - Low inter-lot variability and high long-term stability of ready-to-use and room temperature-stable dry reagents for Basophil Activation Testing against peanut extracts
D3.08 - Biomarker Profiles and Autoimmune Features in Patients with Chronic Urticaria: A Clinical–Laboratory Analysis
D3.09 - Cyto-LTT as a Diagnostic Tool in Acute Drug-Induced Interstitial Nephritis: A Case Report and Laboratory Case Series
D3.10 - An exploratory assessment of biological inflammatory markers found in nasal epithelial cells from rhinitic patients as prospective predictors of rhinitis exacerbation status
D3.11 - Identification of allergens in Chicken and Rabbit meat, a case report
D3.418 - A Phase 1b Study of Lesigercept, a Long-acting High-affinity IgETrap-Fc Fusion Protein: Safety, Tolerability, PK, and PD in Atopic Healthy and Allergic Subjects
D3.419 - Efficacy, safety, and remission outcomes of omalizumab in elderly patients with severe allergic asthma: a subgroup analysis by age of onset
D3.420 - Real-world epidemiologic characteristics of patients treated with dupilumab for type 2 inflammatory indications: a single-center retrospective cohort study
D3.421 - Real-world Effectiveness and Safety of Lanadelumab Treatment in Patients With Hereditary Angioedema: The 12-Month Interim Analysis of a Polish, Prospective, Multicenter, Observational Study (CHOPIN)
D3.422 - Dupilumab in children with multimorbid atopic phenotype: therapy efficacy, safety and biomarker changes
D3.423 - Lanadelumab treatment is effective and safe in patients with Factor XII associated cold-induced autoinflammatory syndrome: results from an open-label proof-of-concept study
D3.424 - Retrospective Analysis of Self-Administration of Biologic Treatments for Severe Asthma and Chronic Urticaria
D3.426 - Predicting response to omalizumab in patients with chronic spontaneous urticaria: The first results of the global multicenter UCARE SCOPUS project
Pagination
Current page
1
Page
2
Next page
Next
Last page
Last
Download the app
The congress at your fingertips
Available on
Download